Celina Whalley, MSc
Celina Whalley is a scientific writer with expertise in genomics, residing in West Midlands, UK.
20+ years of experience working with University Genomic Service laboratories specializing in:
- RNA, DNA and cfDNA extraction, along with QC, from biological samples
- Microarrays for methylation, genotyping, and gene expression
- Next Generation Sequencing (NGS) library preparation with DNA and RNA
- Operation of Illumina sequencing platforms
- Oxford Nanopore long read library preparation with DNA and RNA
- Operation of Oxford Nanopore MinION/GridION and PromethION platforms
- 10x single cell mRNA-seq library preparation and NGS
- BSc Biology, University of Lancaster, UK
- MSc Medical Mycology, University of Leeds, UK
- Registered Scientist (RSci)
- Chartered Scientist (CSci)
Genetic testing company, Nonacus, has launched its latest next generation sequencing (NGS) test in the GALEAS product range – the GALEAS Hereditary Plus panel – which provides laboratories and clinicians with a comprehensive and streamlined way to diagnose patients with cancer that is caused by inherited genetic mutations.
Hereditary cancer testing has become a valuable tool in healthcare, contributing to the understanding and identification of individuals’ susceptibility to cancer.
Effective probe-set design ensures comprehensive target coverage and heightened sensitivity. A poor design can lead to missed opportunities in detecting critical genetic variants.
Explore the transformative power of next-generation sequencing and the mysteries of DNA with our detailed guide on FFPE, cfDNA, and gDNA sample types.
Targeted Next Generation Sequencing (NGS) panels have revolutionized clinical diagnosis and treatment of genetic disorders and cancers by being able to precisely identify disease-associated variants.
Since its introduction into genomics in 1995, Solid Phase Reversible Immobilization (SPRI) technology, in the form of magnetic beads, has become mainstream in laboratory protocols for nucleic acid extraction and purification.
Advanced Genomics APAC Co. Ltd. proudly announced today the grand opening of its Taiwan headquarters, marking a significant milestone in its mission to revolutionize medical diagnosis and advance the field of cancer genomics.
To improve bladder cancer management for both patients and clinicians, Nonacus developed and launched GALEAS Bladder. This urine-based molecular biomarker test is highly accurate and sensitive at detecting all stages and grades of bladder cancer. It provides a simple sample-to-report, molecular triage for patients with hematuria; streamlining the clinical diagnosis process and reducing the need for cystoscopies.
To consolidate multiple testing strategies for haematological malignancies, our customer designed the first Nonacus NGS panel for both myeloid and lymphoid neoplasia
To help consolidate multiple testing strategies for haematological malignancies, our customer designed a Nonacus NGS panel, creating the first NGS workflow for both myeloid and lymphoid neoplasia.
Copy number variants are responsible for 5-10% of genetic disease – that’s why detecting them reliably and robustly is so important in clinical labs. Next Generation Sequencing panels have proven to be extremely useful for clinical applications and can successfully detect many genomic variants, but they can often struggle with CNV detection.